Article Sidebar

Download
PDF
Statistic
Read Counter : 725 Download : 631

Main Article Content

Abstract

Background: Gout is a metabolic disease manifested mainly as an intense monoarticular inflammatory reaction which is strongly associated with hyperuricemia. Latest evidence showed that uric acid exerted effects on the development of other diseases. Many studies in developed countries had estimated the frequency of comorbidities associated with gout such
as hypertension, obesity, diabetes mellitus, Chronic Kidney Disease (CKD), and Myocardial Infarct (MCI). However, no data regarding these frequencies have been found in Indonesia up to now to the best of the author’s knowledge. This study aimed to establish the
frequency of these comorbidities in patients with gout in Rheumatology Clinic Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.

Methods: All medical records of patients with gout in Rheumatology Clinic Dr. Hasan Sadikin General Hospital from January 2012 to December 2013 were collected. The data on blood pressure; Body Mass Index (BMI); random blood glucose, fasting blood glucose or 2 hours
post prandial blood glucose; history of myocardial infarction; and creatinine were taken and analyzed to determine the presence of comorbidities 

Results: Among all patients with gout in Rheumatology Clinic Dr. Hasan Sadikin General Hospital, 53.08% had chronic kidney disease, 42.73 % had hypertension, 25.39% had diabetes mellitus, 15.70% had myocardial infarction and 12.22% had obesity.

Conclusions: Comorbidities commonly found in patients with gout in order of frequency were chronic kidney disease, hypertension, diabetes mellitus, myocardial infarct, and obesity.

Keywords: gout, comorbidities, frequency.

Article Details

How to Cite
Limanjaya, W. R., Wachjudi, R. G., & Tansah, H. (2018). Comorbidities in patients with gout in rheumatology clinic Dr. Hasan Sadikin general hospital in 2012 - 2013. Indonesian Journal of Rheumatology, 8(1). https://doi.org/10.37275/ijr.v8i1.7

References

  1. Keenan RT, Nowatzky J, Pillinger MH. Etiology and Pathogenesis of Hyperuricemia and Gout. In: Firestein GS, Budd RC, Gabriel SE, Mcinnes IB, O’Dell JR, editors. Kelley’s Textbook of Rheumatology. 9th ed. Philadelphia: Elsevier Saunders; 2013. p. 1533–53.
  2. Burns CM, Wortmann RL. Clinical Features and Treatment of Gout. In: Firestein GS, Budd RC, Gabriel SE, Mcinnes IB, O’Dell JR, editors. Kelley’s Textbook of Rheumatology. 9thed. Philadelphia: Elsevier Saunders; 2013.p. 1554–75.
  3. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum 2011;63(10):3136–41.
  4. Pillinger MH, Goldfarb DS, Keenan RT. Gout and its comorbidities. Bull NYU Hosp Jt Dis 2010;68(3):199–203.
  5. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US General Population: NHANES 2007–2008. Am J Med 2012;125(7):679–87.
  6. Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis 2008;67(7):960–6.
  7. Kotchen TA. Hypertensive Vascular Disease. In: Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J, editors. Harrison’s Principle of Internal Medicine. 18 ed. United States: McGrawHill; 2012.p. 2042-59.
  8. Bistrian BR, Driscoll DF. Enteral and Parenteral Nutrition Therapy. In: Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J, editors. Harrison’s Principle of Internal Medicine. 18 ed. United States: McGrawHill; 2012. p. 612-21.
  9. Powers AC. Diabetes Mellitus. In: Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J, editors. Harrison’s Principle of Internal Medicine. 18 ed. United States: McGrawHill; 2012. p. 2968-3002.
  10. Bargman JM, Skorecki K. Chronic Kidney Disease. In: Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J, editors. Harrison’s Principle of Internal Medicine. 18 ed. United States: McGrawHill; 2012. p. 2308-21.
  11. Mikuls T, Farrar J, Bilker W, Fernandes S, Schumacher H, Saag K. Gout epidemiology: results from the UK general practice research database, 1990 – 1999. Ann Rheum Dis 2005;64(2):267–72.
  12. Feig DI, Kang D-H, Johnson RJ. Uric acid and cardiovascular risk. N EnglJ Med 2008;359(17):1811–21.
  13. Kodama S, Saito K, Yachi Y, Asumi M , Sugawara A, Totsuka K, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes care 2009;32(9):1737–42.
  14. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol. 2007;293(2):C584–C96.
  15. Baldwin W, McRae S, Marek G, Wymer D, Pannu V, Baylis C, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome.Diabetes 2011;60(4):1258–69.
  16. Chen JH, Pan WH, Hsu CC, Yeh WT, Chuang SY, Chen PY, et al. Impact of obesity and hypertriglyceridemia on gout development with or without hyperuricemia: a prospective study. Arthritis Care Res 2013;65(1):133–40.
  17. Soriano LC, Rothenbacher D, Choi HK, Rodríguez LAG. Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther 2011;13(2):R39.